A large real-world study presented at the Alzheimer's Association International Conference 2026 in London has found that a blood test for Alzheimer's disease now enables family physicians to diagnose the condition with nearly the same accuracy as dementia specialists, a development that could dramatically expand access to diagnosis for millions of Americans who do not live near specialty care centers.
The study, conducted in Sweden and reported on July 14, 2026, at AAIC 2026 by Sebastian Palmqvist, MD, PhD, a neurologist at Lund University, involved 1,310 patients and 165 physicians in both primary and specialty care settings. Using the PrecivityAD2 blood test, which measures phosphorylated tau protein (p-tau217) and amyloid beta ratios, family doctors who reviewed the blood test results diagnosed Alzheimer's correctly 93 percent of the time, compared to specialists' 94 percent accuracy in the same patient population.
